cardiotomskСибирский журнал клинической и экспериментальной медициныSiberian Journal of Clinical and Experimental Medicine2713-29272713-265XTSU publishing10.29001/2073-8552-2020-35-2-26-34cardiotomsk-971Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESСердечно-сосудистые заболевания и хроническая обструктивная болезнь легких: этиопатогенетическая взаимосвязь и клиническое значение (обзор литературы)Cardiovascular diseases and chronic obstructive pulmonary disease: etiopathogenetic relationship and clinical signifi cance (literature review)https://orcid.org/0000-0002-2712-0227ЧаулинА. М.ChaulinA. M.

врач, 443070, Самара, ул. Аэродромная, 43;

ассистент кафедры, 443099, Самара, ул. Чапаевская, 89

Medical Doctor, Pathologist, 43, Aerodromnaya str., Samara, 443070;

Lecturer Assistant, 89, Chapayevskaya str., Samara, 443099

alekseymichailovich22976@gmail.comhttps://orcid.org/0000-0002-6453-2976ДупляковД. В.DuplyakovD. V.

д-р мед. наук, заместитель главного врача по медицинской части, 443070, Самара, ул. Аэродромная, 43;

профессор кафедры, 443099, Самара, ул. Чапаевская, 89

Dr. Sci. (Med.), Director Deputy for Medical Issues, 43, Aerodromnaya str., Samara, 443070;

Professor, 89, Chapayevskaya str., Samara, 443099

duplyakov@yahoo.comСамарский областной клинический кардиологический диспансер; Самарский государственный медицинский университет Министерства здравоохранения Российской ФедерацииРоссияSamara Regional Cardiology Dispensary; Samara State Medical UniversityRussian Federation2020040720203522634Copyright © Чаулин А.М., Дупляков Д.В., 20202020Чаулин А.М., Дупляков Д.В.Chaulin A.M., Duplyakov D.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.sibjcem.ru/jour/article/view/971

Сердечно-сосудистые заболевания (ССЗ) и хроническая обструктивная болезнь легких (ХОБЛ) часто сосуществуют. Коморбидность ССЗ и ХОБЛ является серьезной современной медико-социальной проблемой. В этой статье рассматриваются основные факторы риска, которые являются общими для ХОБЛ и ССЗ: курение, воспаление, малоподвижный образ жизни, старение, окислительный стресс. Также обсуждаются патогенетические механизмы, лежащие в основе связи между ХОБЛ и ССЗ.

Cardiovascular diseases (CVD) and chronic obstructive pulmonary disease (COPD) often coexist. Comorbidity of CVD and COPD is a serious modern medical and social problem. This article discusses the main risk factors that are common for COPD and CVD: smoking, infl ammation, a sedentary lifestyle, aging, and oxidative stress. Pathogenetic mechanisms underlying the relationship between COPD and CVD are also discussed.

коморбидностьполиморбидностьфакторы рискапатофизиологиясердечно-сосудистые заболеванияхроническая обструктивная болезнь легкихcomorbiditypolymorbidityrisk factorspathophysiologycardiovascular diseasechronic obstructive pulmonary diseaseReferencesFeinstein A.R. The pre-therapeutic classification of comorbidity in chronic disease. J. Chronic. Dis. 1970;23(7):455–468. DOI: 10.1016/0021-9681(70)90054-8.Feinstein A.R. The pre-therapeutic classifi cation of comorbidity in chronic disease. J. Chronic. Dis. 1970;23(7):455–468. DOI: 10.1016/0021-9681(70)90054-8.Тарловская Е.И. Коморбидность и полиморбидность – современная трактовка и насущные задачи, стоящие перед терапевтическим сообществом. Кардиология. 2018;58(S9):29–38. DOI: 10.18087/cardio.2562.Tarlovskaya E.I. Comorbidity and polymorbidity – a modern interpretation and urgent tasks facing the therapeutic community. Kardiologiia. 2018;58(S9):29–38 (In Russ.). DOI: 10.18087/cardio.2562.Turner A., Mulla A., Booth A., Aldridge S., Stevens S., Battye F. et al. An evidence synthesis of the international knowledge base for new care models to inform and mobilise knowledge for multispecialty community providers (MCPs). Syst. Rev. 2016;5(1):167. DOI: 10.1186/s13643-016-0346-x.Turner A., Mulla A., Booth A., Aldridge S., Stevens S., Battye F. et al. An evidence synthesis of the international knowledge base for new care models to inform and mobilise knowledge for multispecialty community providers (MCPs). Syst. Rev. 2016;5(1):167. DOI: 10.1186/s13643-016-0346-x.Violan C., Foguet-Boreu Q., Flores-Mateo G., Salisbury C., Blom J., Freitag M. et al. Prevalence, determinants and patterns of multimorbidity in primary care: А systematic review of observational studies. PLoS One. 2014;9(7):e102149. DOI: 10.1371/journal.pone.0102149.Violan C., Foguet-Boreu Q., Flores-Mateo G., Salisbury C., Blom J., Freitag M. et al. Prevalence, determinants and patterns of multimorbidity in primary care: А systematic review of observational studies. PLoS One. 2014;9(7):e102149. DOI: 10.1371/journal.pone.0102149.Chen W., Thomas J., Sadatsafavi M., FitzGerald J.M. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir. Med. 2015;3(8):631–639. DOI: 10.1016/S2213-2600(15)00241-6.Chen W., Thomas J., Sadatsafavi M., FitzGerald J.M. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir. Med. 2015;3(8):631–639. DOI: 10.1016/S2213-2600(15)00241-6.Roversi S., Fabbri L.M., Sin D.D., Hawkins N.M., Agusti A. Chronic Obstructive Pulmonary Disease and Cardiac Diseases. An Urgent Need for Integrated Care. Am. J. Respir. Crit. Care Med. 2016;194(11):1319–1336. DOI: 10.1164/rccm.201604-0690SO.Roversi S., Fabbri L.M., Sin D.D., Hawkins N.M., Agusti A. Chronic Obstructive Pulmonary Disease and Cardiac Diseases. An Urgent Need for Integrated Care. Am. J. Respir. Crit. Care Med. 2016;194(11):1319–1336. DOI: 10.1164/rccm.201604-0690SO.Mullerova H., Agusti A., Erqou S., Mapel D.W. Cardiovascular comorbidity in COPD: systematic literature review. Chest. 2013;144(4):1163–1178. DOI: 10.1378/chest.12-2847.Mullerova H., Agusti A., Erqou S., Mapel D.W. Cardiovascular comorbidity in COPD: systematic literature review. Chest. 2013;144(4):1163–1178. DOI: 10.1378/chest.12-2847.Григорьева Н.Ю., Майорова М.В., Королёва М.Е., Самолюк М.О. Особенности формирования и развития сердечно-сосудистых заболеваний у больных хронической обструктивной болезнью легких. Терапевтический архив. 2019;91(1):44–47. DOI: 10.26442/00403660.2019.01.000027.Grigoryeva N.Y., Maiorova М.V., Korolyova M.E., Samolyuk M.O. Сomorbidity and polymorbidity of the patient with chronic obstructive pulmonary disease and cardiovascular diseases. Therapeutic Archive. 2019;91(1):44–47. DOI: 10.26442/00403660.2019.01.000027.Lahousse L., Tiemeier H., Ikram M.A., Brusselle G.G. Chronic obstructive pulmonary disease and cerebrovascular disease: A comprehensive review. Respir. Med. 2015;109(11):1371–1380. DOI: 10.1016/j.rmed.2015.07.014.Lahousse L., Tiemeier H., Ikram M.A., Brusselle G.G. Chronic obstructive pulmonary disease and cerebrovascular disease: A comprehensive review. Respir. Med. 2015;109(11):1371–1380. DOI: 10.1016/j.rmed.2015.07.014.Morgan A.D., Sharma C., Rothnie K.J., Potts J., Smeeth L., Quint J.K. Chronic Obstructive Pulmonary Disease and the Risk of Stroke. Ann. Am. Thorac. Soc. 2017;14(5):754–765. DOI: 10.1513/AnnalsATS.201611-932SR.Morgan A.D., Sharma C., Rothnie K.J., Potts J., Smeeth L., Quint J.K. Chronic Obstructive Pulmonary Disease and the Risk of Stroke. Ann. Am. Thorac. Soc. 2017;14(5):754–765. DOI: 10.1513/AnnalsATS.201611-932SR.Houben-Wilke S., Jorres R.A., Bals R., Franssen F.M., Glaser S., Holle R. et al. Peripheral Artery Disease and Its Clinical Relevance in Patients with Chronic Obstructive Pulmonary Disease in the COPD and Systemic Consequences-Comorbidities Network Study. Am. J. Respir. Crit. Care Med. 2017;195(2):189–197. DOI: 10.1164/rccm.201602-0354OC.Houben-Wilke S., Jorres R.A., Bals R., Franssen F.M., Glaser S., Holle R. et al. Peripheral Artery Disease and Its Clinical Relevance in Patients with Chronic Obstructive Pulmonary Disease in the COPD and Systemic Consequences-Comorbidities Network Study. Am. J. Respir. Crit. Care Med. 2017;195(2):189–197. DOI: 10.1164/rccm.201602-0354OC.Brusselle G., Bracke K., De Pauw M. Peripheral аrtery disease in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2017;195(2):148–150. DOI: 10.1164/rccm.201608-1712ED.Brusselle G., Bracke K., De Pauw M. Peripheral аrtery disease in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2017;195(2):148–150. DOI: 10.1164/rccm.201608-1712ED.Franssen F.M., Soriano J.B., Roche N., Bloomfield P.H., Brusselle G., Fabbri L.M. et al. Lung function abnormalities in smokers with ischemic heart disease. Am. J. Respir. Crit. Care Med. 2016;194(5):568–576. DOI: 10.1164/rccm.201512-2480OC.Franssen F.M., Soriano J.B., Roche N., Bloomfi eld P.H., Brusselle G., Fabbri L.M. et al. Lung function abnormalities in smokers with ischemic heart disease. Am. J. Respir. Crit. Care Med. 2016;194(5):568–576. DOI: 10.1164/rccm.201512-2480OC.Divo M., Cote C., de Torres J.P., Casanova C., Marin J.M., Pinto-Plata V. et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2012;186(2):155– 161. DOI: 10.1164/rccm.201201-0034OC.Divo M., Cote C., de Torres J.P., Casanova C., Marin J.M., Pinto-Plata V. et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2012;186(2):155– 161. DOI: 10.1164/rccm.201201-0034OC.Беленков Ю.Н., Цветкова О.А., Привалова Е.В., Ан Г.В., Ильгисонис И.С., Воронкова О.О. Коморбидность хронической обструктивной болезни легких и сердечно-сосудистых заболеваний: место терапии современными β-адреноблокаторами. Кардиология. 2019;59(6):48– 55. DOI: 10.18087/cardio.2019.6.n458.Belenkov Y.N., Tsvetkova O.A., Privalova E.V., An G.V., Ilgisonis I.S., Voronkova O.O. Comorbidity of chronic obstructive pulmonary disease and cardiovascular diseases: Place of therapy with modern β-adrenoblockers. Kardiologiia. 2019;59(6):48–55 (In Russ.). DOI: 10.18087/cardio.2019.6.n458.Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135–1143. DOI: 10.1161/hc0902.104353.Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135–1143. DOI: 10.1161/hc0902.104353.Paulus W.J., Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J. Am. Coll. Cardiol. 2013;62(4):263–271. DOI: 10.1016/j.jacc.2013.02.092.Paulus W.J., Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J. Am. Coll. Cardiol. 2013;62(4):263–271. DOI: 10.1016/j.jacc.2013.02.092.Gan W.Q., Man S.F., Senthilselvan A., Sin D.D. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59(7):574–580. DOI: 10.1136/thx.2003.019588.Gan W.Q., Man S.F., Senthilselvan A., Sin D.D. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59(7):574–580. DOI: 10.1136/thx.2003.019588.De Torres J.P., Cordoba-Lanus E., Lopez-Aguilar C., de Fuentes M.M., de Garcini M.A., Aguirre-Jaime A. et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur. Respir. J. 2006;27(5):902–907. DOI: 10.1183/09031936.06.00109605.De Torres J.P., Cordoba-Lanus E., Lopez-Aguilar C., de Fuentes M.M., de Garcini M.A., Aguirre-Jaime A. et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur. Respir. J. 2006;27(5):902–907. DOI: 10.1183/09031936.06.00109605.Hurst J.R., Donaldson G.C., Perera W.R., Wilkinson T.M., Bilello J.A., Hagan G.W. et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2006; 174(8):867–874. DOI: 10.1164/rccm.200604-506OC.Hurst J.R., Donaldson G.C., Perera W.R., Wilkinson T.M., Bilello J.A., Hagan G.W. et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2006;174(8):867–874. DOI: 10.1164/rccm.200604-506OC.Sin D.D., Man S.F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107(11):1514–1519. DOI: 10.1161/01.cir.0000056767.69054.b3.Sin D.D., Man S.F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107(11):1514–1519. DOI: 10.1161/01.cir.0000056767.69054.b3.Roversi S., Roversi P., Spadafora G., Rossi R., Fabbri L.M. Coronary artery disease concomitant with chronic obstructive pulmonary disease. Eur. J. Clin. Invest. 2014;44(1):93–102. DOI: 10.1111/eci.12181.Roversi S., Roversi P., Spadafora G., Rossi R., Fabbri L.M. Coronary artery disease concomitant with chronic obstructive pulmonary disease. Eur. J. Clin. Invest. 2014;44(1):93–102. DOI: 10.1111/eci.12181.Celli B.R., Locantore N., Yates J., Tal-Singer R., Miller B.E., Bakke P. et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2012;185(10):1065–1072. DOI: 10.1164/rccm.201110-1792OC.Celli B.R., Locantore N., Yates J., Tal-Singer R., Miller B.E., Bakke P. et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2012;185(10):1065–1072. DOI: 10.1164/rccm.201110-1792OC.Man S.F., Connett J.E., Anthonisen N.R., Wise R.A., Tashkin D.P., Sin D.D. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax. 2006;61(10):849–853. DOI: 10.1136/thx.2006.059808.Man S.F., Connett J.E., Anthonisen N.R., Wise R.A., Tashkin D.P., Sin D.D. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax. 2006;61(10):849–853. DOI: 10.1136/thx.2006.059808.Marchetti N., Ciccolella D.E., Jacobs M.R., Crookshank A., Gaughan J.P., Kashem M.A. et al. Hospitalized acute exacerbation of COPD impairs flow and nitroglycerin-mediated peripheral vascular dilation. COPD. 2011;8(2):60–65. DOI: 10.3109/15412555.2011.558541.Marchetti N., Ciccolella D.E., Jacobs M.R., Crookshank A., Gaughan J.P., Kashem M.A. et al. Hospitalized acute exacerbation of COPD impairs flow and nitroglycerin-mediated peripheral vascular dilation. COPD. 2011;8(2):60–65. DOI: 10.3109/15412555.2011.558541.Maclay J.D., MacNee W. Cardiovascular disease in COPD: mechanisms. Chest. 2013;143(3):798–807. DOI: 10.1378/chest.12-0938.Maclay J.D., MacNee W. Cardiovascular disease in COPD: mechanisms. Chest. 2013;143(3):798–807. DOI: 10.1378/chest.12-0938.Criner G.J., Connett J.E., Aaron S.D., Albert R.K., Bailey W.C., Casaburi R. et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N. Engl. J. Med. 2014;370(23):2201–2210. DOI: 10.1056/NEJMoa1403086.Criner G.J., Connett J.E., Aaron S.D., Albert R.K., Bailey W.C., Casaburi R. et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N. Engl. J. Med. 2014;370(23):2201–2210. DOI: 10.1056/NEJMoa1403086.John M.E., Cockcroft J.R., McKeever T.M., Coward W.R., Shale D.J., Johnson S.R. et al. Cardiovascular and inflammatory effects of simvastatin therapy in patients with COPD: a randomized controlled trial. Int. J. Chron. Obstruct. Pulmon. Dis. 2015;10:211–221. DOI: 10.2147/COPD.S76061.John M.E., Cockcroft J.R., McKeever T.M., Coward W.R., Shale D.J., Johnson S.R. et al. Cardiovascular and inflammatory effects of simvastatin therapy in patients with COPD: a randomized controlled trial. Int. J. Chron. Obstruct. Pulmon. Dis. 2015;10:211–221. DOI: 10.2147/COPD. S76061.Seidel D., Cheung A., Suh E.S., Raste Y., Atakhorrami M., Spruit M.A. Physical inactivity and risk of hospitalisation for chronic obstructive pulmonary disease. Int. J. Tuberc. Lung Dis. 2012;16(8):1015–1019. DOI: 10.5588/ijtld.12.0050.Seidel D., Cheung A., Suh E.S., Raste Y., Atakhorrami M., Spruit M.A. Physical inactivity and risk of hospitalisation for chronic obstructive pulmonary disease. Int. J. Tuberc. Lung Dis. 2012;16(8):1015–1019. DOI: 10.5588/ijtld.12.0050.Van Remoortel H., Hornikx M., Langer D., Burtin C., Everaerts S., Verhamme P. et al. Risk factors and comorbidities in the preclinical stages of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2014;189(1):30–38. DOI: 10.1164/rccm.201307-1240OC.Van Remoortel H., Hornikx M., Langer D., Burtin C., Everaerts S., Verhamme P. et al. Risk factors and comorbidities in the preclinical stages of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2014;189(1):30–38. DOI: 10.1164/rccm.201307-1240OC.Katajisto M., Kupiainen H., Rantanen P., Lindqvist A., Kilpelainen M, Tikkanen H. et al. Physical inactivity in COPD and increased patient perception of dyspnea. Int. J. Chron. Obstruct. Pulmon. Dis. 2012;7:743–755. DOI: 10.2147/COPD.S35497.Katajisto M., Kupiainen H., Rantanen P., Lindqvist A., Kilpelainen M, Tikkanen H. et al. Physical inactivity in COPD and increased patient perception of dyspnea. Int. J. Chron. Obstruct. Pulmon. Dis. 2012;7:743–755. DOI: 10.2147/COPD.S35497.Barnes P.J. Senescence in COPD and Its Comorbidities. Ann. Rev. Physiol. 2017;79:517–539. DOI: 10.1146/annurev-physiol-022516-034314.Barnes P.J. Senescence in COPD and Its Comorbidities. Ann. Rev. Physiol. 2017;79:517–539. DOI: 10.1146/annurev-physiol-022516-034314.Savale L., Chaouat A., Bastuji-Garin S., Marcos E., Boyer L., Maitre B. et al. Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2009;179(7):566–571. DOI: 10.1164/rccm.200809-1398OC.Savale L., Chaouat A., Bastuji-Garin S., Marcos E., Boyer L., Maitre B. et al. Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2009;179(7):566–571. DOI: 10.1164/rccm.200809-1398OC.Tsuji T., Aoshiba K., Nagai A. Alveolar cell senescence in patients with pulmonary emphysema. Am. J. Respir. Crit. Care Med. 2006;174(8):886– 893. DOI: 10.1164/rccm.200509-1374OC.Tsuji T., Aoshiba K., Nagai A. Alveolar cell senescence in patients with pulmonary emphysema. Am. J. Respir. Crit. Care Med. 2006;174(8):886– 893. DOI: 10.1164/rccm.200509-1374OC.Tuder R.M., Yoshida T., Fijalkowka I., Biswal S., Petrache I. Role of lung maintenance program in the heterogeneity of lung destruction in emphysema. Proc. Am. Thorac. Soc. 2006;3(8):673–679. DOI: 10.1513/pats.200605-124SF.Tuder R.M., Yoshida T., Fijalkowka I., Biswal S., Petrache I. Role of lung maintenance program in the heterogeneity of lung destruction in emphysema. Proc. Am. Thorac. Soc. 2006;3(8):673–679. DOI: 10.1513/pats.200605-124SF.Benetos A., Okuda K., Lajemi M., Kimura M., Thomas F., Skurnick J. et al. Telomere length as an indicator of biological aging: the gender effect and relation with pulse pressure and pulse wave velocity. Hypertension. 2001;37(2Pt2):381–385. DOI: 10.1161/01.hyp.37.2.381.Benetos A., Okuda K., Lajemi M., Kimura M., Thomas F., Skurnick J. et al. Telomere length as an indicator of biological aging: the gender effect and relation with pulse pressure and pulse wave velocity. Hypertension. 2001;37(2Pt2):381–385. DOI: 10.1161/01.hyp.37.2.381.Minamino T., Miyauchi H., Yoshida T., Ishida Y., Yoshida H., Komuro I. Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation. 2002;105(13):1541–1544. DOI: 10.1161/01.cir.0000013836.85741.17.Minamino T., Miyauchi H., Yoshida T., Ishida Y., Yoshida H., Komuro I. Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation. 2002;105(13):1541–1544. DOI: 10.1161/01.cir.0000013836.85741.17.Maclay J.D., McAllister D.A., Rabinovich R., Haq I., Maxwell S., Hartland S. et al. Systemic elastin degradation in chronic obstructive pulmonary disease. Thorax. 2012;67(7):606–612. DOI: 10.1136/thoraxjnl-2011- 200949.Maclay J.D., McAllister D.A., Rabinovich R., Haq I., Maxwell S., Hartland S. et al. Systemic elastin degradation in chronic obstructive pulmonary disease. Thorax. 2012;67(7):606–612. DOI: 10.1136/thoraxjnl-2011-200949.Sciurba F.C., Rogers R.M., Keenan R.J., Slivka W.A., Gorcsan J., Ferson P.F. et al. Improvement in pulmonary function and elastic recoil after lung-reduction surgery for diffuse emphysema. N. Engl. J. Med. 1996;334(17):1095–1099. DOI: 10.1056/NEJM199604253341704.Sciurba F.C., Rogers R.M., Keenan R.J., Slivka W.A., Gorcsan J., Ferson P.F. et al. Improvement in pulmonary function and elastic recoil after lung-reduction surgery for diffuse emphysema. N. Engl. J. Med. 1996;334(17):1095–1099. DOI: 10.1056/NEJM199604253341704.Falk J.A., Martin U.J., Scharf S., Criner G.J. Lung elastic recoil does not correlate with pulmonary hemodynamics in severe emphysema. Chest. 2007;132(5):1476–1484. DOI: 10.1378/chest.07-0041.Falk J.A., Martin U.J., Scharf S., Criner G.J. Lung elastic recoil does not correlate with pulmonary hemodynamics in severe emphysema. Chest. 2007;132(5):1476–1484. DOI: 10.1378/chest.07-0041.Austin V., Crack P.J., Bozinovski S., Miller A.A., Vlahos R. COPD and stroke: are systemic inflammation and oxidative stress the missing links? Clin. Sci. (Lond.). 2016;130(13):1039–1050. DOI: 10.1042/CS20160043.Austin V., Crack P.J., Bozinovski S., Miller A.A., Vlahos R. COPD and stroke: are systemic inflammation and oxidative stress the missing links? Clin. Sci. (Lond.). 2016;130(13):1039–1050. DOI: 10.1042/CS20160043.Kida Y., Goligorsky M.S. Sirtuins, Cell Senescence, and Vascular Aging. Can. J. Cardiol. 2016;32(5):634–641. DOI: 10.1016/j.cjca.2015.11.022.Kida Y., Goligorsky M.S. Sirtuins, Cell Senescence, and Vascular Aging. Can. J. Cardiol. 2016;32(5):634–641. DOI: 10.1016/j.cjca.2015.11.022.Wright J.L., Petty T., Thurlbeck W.M. Analysis of the structure of the muscular pulmonary arteries in patients with pulmonary hypertension and COPD: National Institutes of Health nocturnal oxygen therapy trial. Lung. 1992;170(2):109–124. DOI: 10.1007/bf00175982.Wright J.L., Petty T., Thurlbeck W.M. Analysis of the structure of the muscular pulmonary arteries in patients with pulmonary hypertension and COPD: National Institutes of Health nocturnal oxygen therapy trial. Lung. 1992;170(2):109–124. DOI: 10.1007/bf00175982.Dinh-Xuan A.T., Higenbottam T.W., Clelland C.A., Pepke-Zaba J., Cremona G., Butt A.Y. et al. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N. Engl. J. Med. 1991;324(22):1539–1547. DOI: 10.1056/NEJM199105303242203.Dinh-Xuan A.T., Higenbottam T.W., Clelland C.A., Pepke-Zaba J., Cremona G., Butt A.Y. et al. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N. Engl. J. Med. 1991;324(22):1539–1547. DOI: 10.1056/NEJM199105303242203.Cohen A.J., Brauer M., Burnett R., Anderson H.R., Frostad J., Estep K. et al. Estimates and 25-year trends of the global burden of disease attributable to ambient air pollution: an analysis of data from the Global Burden of Diseases Study 2015. Lancet. 2017;389(10082):1907–1918. DOI: 10.1016/S0140-6736(17)30505-6.Cohen A.J., Brauer M., Burnett R., Anderson H.R., Frostad J., Estep K. et al. Estimates and 25-year trends of the global burden of disease attributable to ambient air pollution: an analysis of data from the Global Burden of Diseases Study 2015. Lancet. 2017;389(10082):1907–1918. DOI: 10.1016/S0140-6736(17)30505-6.Chaudary N., Geraci S.A. Prognostic value of cardiac-specifi c troponins in chronic obstructive pulmonary disease exacerbations: a systematic review. J. Miss. State Med. Assoc. 2014;55(2):40–44.Chaudary N., Geraci S.A. Prognostic value of cardiac-specific troponins in chronic obstructive pulmonary disease exacerbations: a systematic review. J. Miss. State Med. Assoc. 2014;55(2):40–44.Harvey M.G., Hancox R.J. Elevation of cardiac troponins in exacerbation of chronic obstructive pulmonary disease. Emerg. Med. Australas. 2004;16(3):212–215. DOI: 10.1111/j.1742-6723.2004.00589.x.Harvey M.G., Hancox R.J. Elevation of cardiac troponins in exacerbation of chronic obstructive pulmonary disease. Emerg. Med. Australas. 2004;16(3):212–215. DOI: 10.1111/j.1742-6723.2004.00589.x.Чаулин А.М., Карслян Л.С., Базюк Е.В., Нурбалтаева Д.А., Дупляков Д.В. Клинико-диагностическая ценность кардиомаркеров в биологических жидкостях человека. Кардиология. 2019;59(11):66– 75. DOI: 10.18087/cardio.2019.11.n414.Chaulin A.M., Karslyan L.S., Bazyuk E.V., Nurbaltaeva D.A., Duplyakov D.V. Clinical and diagnostic value of cardiac markers in human biological fluids. Kardiologiia. 2019;59(11):66–75 (In Russ.). DOI: 10.18087/cardio.2019.11.n414.Чаулин А.М., Карслян Л.С., Григорьева Е.В., Нурбалтаева Д.А., Дупляков Д.В. Особенности метаболизма сердечных тропонинов (обзор литературы). Комплексные проблемы сердечно-сосудистых заболеваний. 2019;8(4):103–115. DOI: 10.17802/2306-1278-2019-8-4-103-115.Chaulin A.M., Karslyan L.S., Grigorieva E.V., Nurbaltaeva D.A., Duplyakov D.V. Metabolism of cardiac troponins (literature review). Complex Issues of Cardiovascular Diseases. 2019;8(4):103–115 (In Russ.). DOI: 10.17802/2306-1278-2019-8-4-103-115.Чаулин А.М., Дупляков Д.В. Повышение кардиальных тропонинов, не ассоциированное с острым коронарным синдромом. Часть 1. Кардиология: новости, мнения, обучение. 2019;7(2):13–23. DOI: 10.24411/2309-1908-2019-12002.Chaulin A.M., Duplyakov D.V. Increased cardiac troponins, not associated with acute coronary syndrome. Part 1. Cardiology: News, Opinions, Training. 2019;7(2):13–23 (In Russ.). DOI: 10.24411/2309-1908-2019-12002.Чаулин А.М., Дупляков Д.В. Повышение кардиальных тропонинов, не ассоциированное с острым коронарным синдромом. Часть 2. Кардиология: новости, мнения, обучение. 2019;7(2):24–35. DOI: 10.24411/2309-1908-2019-12003.Chaulin A.M., Duplyakov D.V. Increased cardiac troponins, not associated with acute coronary syndrome. Part 2. Cardiology: News, Opinions, Training. 2019;7(2):24–35 (In Russ.). DOI: 10.24411/2309-1908-2019-12003.Waschki B., Alter P., Zeller T., Magnussen C., Neumann J.T., Twerenbold R. et al. High-sensitivity troponin I and all-cause mortality in patients with stable COPD: An analysis of the COSYCONET study. Eur. Respir. J. 2019;12:1901314. DOI: 10.1183/13993003.01314-2019.Waschki B., Alter P., Zeller T., Magnussen C., Neumann J.T., Twerenbold R. et al. High-sensitivity troponin I and all-cause mortality in patients with stable COPD: An analysis of the COSYCONET study. Eur. Respir. J. 2019;12:1901314. DOI: 10.1183/13993003.01314-2019.Lahousse L., Verhamme K.M., Stricker B.H., Brusselle G.G. Cardiac eff ects of current treatments of chronic obstructive pulmonary disease. Lancet Respir. Med. 2016;4(2):149–164. DOI: 10.1016/S2213-2600(15)00518-4.Lahousse L., Verhamme K.M., Stricker B.H., Brusselle G.G. Cardiac effects of current treatments of chronic obstructive pulmonary disease. Lancet Respir. Med. 2016;4(2):149–164. DOI: 10.1016/S2213-2600(15)00518-4.Decramer M., Janssens W. Chronic obstructive pulmonary disease and comorbidities. Lancet Respir. Med. 2013;1(1):73–83. DOI: 10.1016/S2213-2600(12)70060-7.Decramer M., Janssens W. Chronic obstructive pulmonary disease and comorbidities. Lancet Respir. Med. 2013;1(1):73–83. DOI: 10.1016/ S2213-2600(12)70060-7.Gershon A., Croxford R., Calzavara A., To T., Stanbrook M.B., Upshur R. et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern. Med. 2013;173(13):1175–1185. DOI: 10.1001/jamainternmed.2013.1016.Gershon A., Croxford R., Calzavara A., To T., Stanbrook M.B., Upshur R. et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern. Med. 2013;173(13):1175–1185. DOI: 10.1001/jamainternmed.2013.1016.Heindl S., Lehnert M., Criee C.P., Hasenfuss G., Andreas S. Marked sympathetic activation in patients with chronic respiratory failure. Am. J. Respir. Crit. Care Med. 2001;164(4):597–601. DOI: 10.1164/ajrccm.164.4.2007085.Heindl S., Lehnert M., Criee C.P., Hasenfuss G., Andreas S. Marked sympathetic activation in patients with chronic respiratory failure. Am. J. Respir. Crit. Care Med. 2001;164(4):597–601. DOI: 10.1164/ajrccm.164.4.2007085.Donohue J.F., Hanania N.A., Make B., Miles M.C., Mahler D.A., Curry L. et al. One-year safety and effi cacy study of arformoterol tartrate in patients with moderate to severe COPD. Chest. 2014;146(6):1531–1542. DOI: 10.1378/chest.14-0117.Donohue J.F., Hanania N.A., Make B., Miles M.C., Mahler D.A., Curry L. et al. One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. Chest. 2014;146(6):1531–1542. DOI: 10.1378/chest.14-0117.Dong Y.H., Lin H.H., Shau W.Y., Wu Y.C., Chang C.H., Lai M.S. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax. 2013;68(1):48–56. DOI: 10.1136/thoraxjnl-2012-201926.Dong Y.H., Lin H.H., Shau W.Y., Wu Y.C., Chang C.H., Lai M.S. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax. 2013;68(1):48–56. DOI: 10.1136/thoraxjnl-2012-201926.Agustí A., Noell G., Brugada J., Faner R. Lung function in early adulthood and health in later life: a transgenerational cohort analysis. Lancet Respir. Med. 2017;5(12):935–945. DOI: 10.1016/S2213-2600(17)30434-4.Agustí A., Noell G., Brugada J., Faner R. Lung function in early adulthood and health in later life: a transgenerational cohort analysis. Lancet Respir. Med. 2017;5(12):935–945. DOI: 10.1016/S2213-2600(17)30434-4.Rothnie K.J., Smeeth L., Herrett E., Pearce N., Hemingway H., Wedzicha J. et al. Closing the mortality gap after a myocardial infarction in people with and without chronic obstructive pulmonary disease. Heart. 2015;101(14):1103–1110. DOI: 10.1136/heartjnl-2014-307251.Rothnie K.J., Smeeth L., Herrett E., Pearce N., Hemingway H., Wedzicha J. et al. Closing the mortality gap after a myocardial infarction in people with and without chronic obstructive pulmonary disease. Heart. 2015;101(14):1103–1110. DOI: 10.1136/heartjnl-2014-307251.Quint J.K., Herrett E., Bhaskaran K., Timmis A., Hemingway H., Wedzicha J.A. et al. Eff ect of β blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare records. BMJ. 2013;347:f6650. DOI: 10.1136/bmj.f6650.Quint J.K., Herrett E., Bhaskaran K., Timmis A., Hemingway H., Wedzicha J.A. et al. Effect of β blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare records. BMJ. 2013;347:f6650. DOI: 10.1136/bmj.f6650.Lipworth B., Wedzicha J., Devereux G., Vestbo J., Dransfi eld M.T. Beta-blockers in COPD: time for reappraisal. Eur. Respir. J. 2016;48(3):880– 888. DOI: 10.1183/13993003.01847-2015.Lipworth B., Wedzicha J., Devereux G., Vestbo J., Dransfi eld M.T. Beta-blockers in COPD: time for reappraisal. Eur. Respir. J. 2016;48(3):880– 888. DOI: 10.1183/13993003.01847-2015.

The authors declare that there are no conflicts of interest present.